Ming Cui

Dr. Ming Cui

Department of General Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
YHYa Hu
Ya Hu
XZXiang Zhang
Xiang Zhang
OWOu Wang
Ou Wang
YBYalan Bi
Yalan Bi
XXXiaoping Xing
Xiaoping Xing
YZYupei Zhao
Yupei Zhao

26 January 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
XWXing Wang
Xing Wang
XLXiyuan Luo
Xiyuan Luo
RXRuiling Xiao
Ruiling Xiao
XLXiaohong Liu
Xiaohong Liu
FZFeihan Zhou
Feihan Zhou
YZYupei Zhao
Yupei Zhao
Cancer cells orchestrate a highly dynamic and interconnected network spanning metabolic, epigenetic, and immune mechanisms to drive adaptive plasticity and continuous development. This review synthesizes emerging insights into the coevolutionary strategies employed by malignant and stromal cells—particularly tumor cells and immune populations—across the continuum of tumorigenesis, metastasis, and treatment resistance. During tumor initiation, cancer cells rewire metabolism and generate oncometabolites that reshape the chromatin architecture to support immune evasion. Concurrently, metabolic competition in the tumor microenvironment (TME) induces epigenetic exhaustion of cytotoxic T cells, whereas tumor-associated myeloid cells adopt immunosuppressive and angiogenic phenotypes via metabolite-dependent histone modifications to promote carcinogenesis. At metastatic frontiers, under the local metabolic pressure of target organs, tumor cells undergo epigenetic reprogramming to evade immune attacks and support colonization. Premetastatic niches are preconditioned through exosome-mediated transfer of metabolic enzymes and noncoding RNAs that reprogram resident cells before tumor cells arrive. In cancer immunotherapy, tumors often exploit metabolic adaptative strategies to inhibit cell death signaling pathways or the compensatory activation of self-protective mechanisms to circumvent immune-mediated cytotoxicity and develop resistance to immunotherapy. By mapping these dynamic interactions, we propose a novel conceptual framework of the “metabolic-epigenetic-immune axis” that transcends traditional compartmentalized approaches and helps to identify nodal convergence points for therapeutic co-targeting. This review also prioritizes multitarget inhibitors arising from the convergence of metabolic reprogramming, epigenetic plasticity, and immune evasion networks. An integrated approach to these pathways advances next-generation precision oncology strategies aimed at circumventing the evolutionary resilience of cancer.

3 December 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
Ming CuiMing Cui
Ming Cui
YHYa Hu
Ya Hu
YBYalan Bi
Yalan Bi
WWWeiwei Wang
Weiwei Wang
MWMengyi Wang
Mengyi Wang
YZYupei Zhao
Yupei Zhao

25 September 2017 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
YHYa Hu
Ya Hu
Ming CuiMing Cui
Ming Cui
ZSZhengyi Sun
Zhengyi Sun
ZSZhe Su
Zhe Su
XGXiang Gao
Xiang Gao
YZYupei Zhao
Yupei Zhao
Background. Primary hyperparathyroidism (pHPT) in pregnancy is a rare event, but it poses a significant risk to mothers and fetuses. The optimal treatment strategy remains controversial. Methods. We present a consecutive series of twelve pregnant women with pHPT. Results. Twelve women were diagnosed with pHPT during pregnancy or in the postpartum period. Four of them presented no symptoms or mild symptoms. Four patients experienced serious complications, including hypercalcaemic crisis, acute pancreatitis, and eclampsia. Another four patients were identified postpartum as the result of neonatal convulsion with hypocalcaemia. Minimally invasive parathyroidectomy (MIP) under cervical plexus block was successfully performed in 11 of them during pregnancy or postpartum. The serum levels of ionized calcium and intact parathyroid hormone (iPTH) were much higher in patients with severe complications in this cohort than those in the group of patients with no symptoms or mild symptoms and patients who were diagnosed postpartum. Conclusions. MIP under cervical plexus block might be a safe and effective treatment for pregnant women with pHPT. Even though both conservative and surgical treatments are applicable for most mothers and fetuses with asymptomatic and mild hyperparathyroidism, serious complications may have catastrophic consequences for both.

2 June 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
DJDecheng Jiang
Decheng Jiang
RXRuiling Xiao
Ruiling Xiao
JBJialu Bai
Jialu Bai
XWXing Wang
Xing Wang
YFYuan Fang
Yuan Fang
YZYupei Zhao
Yupei Zhao
The advent of the omics era has facilitated the identification of precise biomarkers for cancer progression, revealing a broader diversity of macrophage phenotypes beyond the traditional M1/M2 classification. Folate receptor 2 (FOLR2)-positive macrophages, co-expressing markers such as mannose receptor C-Type 1 (MRC1/CD206) and lymphatic vessel endothelial hyaluronan receptor 1(LYVE1), are an embryonically derived subset typically found around blood vessels in both tumor stroma and normal tissues. Despite FOLR2’s longstanding association with anti-inflammatory, immunosuppressive macrophages in tumors, its precise role in cancer progression remains unclear. Recent studies suggest that FOLR2+ macrophages can either promote or inhibit cancer progression, depending on their multifaceted roles in the tumor microenvironment. This review provides a comprehensive overview of the biological features, functional roles, molecular mechanisms, and therapeutic potential of FOLR2+ macrophages in cancer.

2 February 2024 in Cancer Letters
Verified
Journal Article
Closed access
JRJie Ren
Jie Ren
BRBo Ren
Bo Ren
XLXiaohong Liu
Xiaohong Liu
Ming CuiMing Cui
Ming Cui
FYFang Yuan
Fang Yuan
YZYupei Zhao
Yupei Zhao